CFC Planning Company’s PTC Therapeutics PTCT Stock Holding History

CFC Planning Company’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-4,537	Closed	-$222K	–	114
2025 Q2	$222K	Buy	+4,537	New	+$215K	0.21%	76

Other funds holding PTCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CFC Planning Company's PTCT Position: Q3 2025 in Review

CFC Planning Company sold out of PTC Therapeutics (PTCT) in Q3 2025, closing a stake of 4,537 shares — an estimated $222K sold.

CFC Planning Company first reported a position in PTCT in Q2 2025 and held it in 1 quarter. The position peaked at $222K in Q2 2025. 293 funds tracked by Wall St. Rank hold PTCT as of Q3 2025.

CFC Planning Company reported no remaining PTC Therapeutics position as of Q3 2025 after selling out during the quarter.
CFC Planning Company sold 4,537 PTC Therapeutics shares in Q3 2025, an estimated $222K.
CFC Planning Company first reported a position in PTC Therapeutics in Q2 2025 and held it in 1 quarter.
CFC Planning Company's PTC Therapeutics position peaked at $222K in Q2 2025.
293 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2025.

Based on CFC Planning Company's 13F filing for Q3 2025, filed 29 Oct 2025.